179 related articles for article (PubMed ID: 11332317)
1. Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update).
Levine M;
CMAJ; 2001 Jan; 164(2):213. PubMed ID: 11332317
[No Abstract] [Full Text] [Related]
2. Chemotherapy for older women with node-positive breast cancer.
Ginsburg D
CMAJ; 2001 Sep; 165(5):525, 527. PubMed ID: 11563200
[No Abstract] [Full Text] [Related]
3. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
4. Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Levine M;
CMAJ; 2001 Mar; 164(5):644-6. PubMed ID: 11258212
[No Abstract] [Full Text] [Related]
5. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
6. Estimating the benefits of adjuvant systemic therapy for women with early breast cancer.
Grogan M; Tabar L; Chua B; Chen HH; Boyages J
Br J Surg; 2001 Nov; 88(11):1513-8. PubMed ID: 11683751
[TBL] [Abstract][Full Text] [Related]
7. Systemic adjuvant therapy for breast cancer.
Reed EC
Nebr Med J; 1996 Mar; 81(3):48-50. PubMed ID: 8907820
[TBL] [Abstract][Full Text] [Related]
8. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
Winer E
Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
[No Abstract] [Full Text] [Related]
9. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
12. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
[TBL] [Abstract][Full Text] [Related]
13. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
14. Advances in adjuvant hormonal therapy for postmenopausal women.
Strasser-Weippl K; Goss PE
J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
[No Abstract] [Full Text] [Related]
15. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
17. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands.
Sukel MP; van de Poll-Franse LV; Nieuwenhuijzen GA; Vreugdenhil G; Herings RM; Coebergh JW; Voogd AC
Eur J Cancer; 2008 Sep; 44(13):1846-54. PubMed ID: 18640030
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
[No Abstract] [Full Text] [Related]
19. Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q & A and case study sampling.
Mamounas E; Budd GT; Miller K
Clin Adv Hematol Oncol; 2008 Feb; 6(2):s1-s8. PubMed ID: 18516819
[No Abstract] [Full Text] [Related]
20. Adjuvant systemic therapy for early breast cancer: progress and controversies.
Hortobagyi GN
Clin Cancer Res; 2001 Jul; 7(7):1839-42. PubMed ID: 11448893
[No Abstract] [Full Text] [Related]
[Next] [New Search]